FeesSafety
Pluang+

Orchid Island Capital reports Q3 2026 GAAP loss of $0.90 per share, matching estimates amid mortgage-backed securities losses.

Market News
23 Oct 2026
Tokenpost
View Source
Bearish
Orchid Island Capital reports Q3 2026 GAAP loss of $0.90 per share, matching estimates amid mortgage-backed securities losses.

Orchid Island Capital, Inc. announced a GAAP loss of $0.90 per share for the third quarter of 2026, aligning with its preliminary forecast. The company earned net interest income of $59.1 million, or $0.30 per common share, while total expenses were $6.3 million, or $0.03 per share. Losses included net realized and unrealized losses on mortgage-backed securities and derivatives, which impacted overall results. This report confirms the company's earlier estimates and highlights challenges in its mortgage-backed securities portfolio.

Orchid Island Capital reported a GAAP loss of $0.90 per share for Q3 2026, confirming its earlier forecast. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 23, 2026 20:03 WIB: out of 50 priced assets, 29 rose and 20 fell. Notable movers include ONE (Harmony) at Rp26 with a 1-day change of +2.48% and Pluang order activity of 56% Sell / 44% Buy, SAND (The Sandbox) at Rp949 down 2.39% with 28% Sell / 72% Buy, and XNO (Nano) at Rp6,204 up 2.26% with 13% Sell / 87% Buy activity.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
1 hour ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
2 hours ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
2 hours ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
2 hours ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App